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An investigation of structural stability in protein-
ligand complexes reveals the balance between
order and disorder
Maciej Majewski 1, Sergio Ruiz-Carmona 1 & Xavier Barril 1,2
The predominant view in structure-based drug design is that small-molecule ligands, once
bound to their target structures, display a well-defined binding mode. However, structural
stability (robustness) is not necessary for thermodynamic stability (binding affinity). In fact, it
entails an entropic penalty that counters complex formation. Surprisingly, little is known
about the causes, consequences and real degree of robustness of protein-ligand complexes.
Since hydrogen bonds have been described as essential for structural stability, here we
investigate 469 such interactions across two diverse structure sets, comprising of 79 drug-
like and 27 fragment ligands, respectively. Completely constricted protein-ligand complexes
are rare and may fulfill a functional role. Most complexes balance order and disorder by
combining a single anchoring point with looser regions. 25% do not contain any robust
hydrogen bond and may form loose structures. Structural stability analysis reveals a hidden
layer of complexity in protein-ligand complexes that should be considered in ligand design.
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B iomolecular systems present a large number of degrees offreedom and must find a suitable balance between orderand disorder. In the particular case of non-covalent com-
plexes, they can exist in a continuum spectrum of possibilities,
ranging from the lock-and-key model to extreme disorder1,2.
While the importance of target flexibility is well-appreciated in
drug discovery3, the flexibility of small-molecule ligands in their
bound state has attracted much less attention. Detailed analyses
reveal that ligands often retain residual mobility4–6. However,
changes in binding mode are more the exception than the
norm7,8 and ligand design based on rigid crystallographic geo-
metries has been remarkably successful9. Explicit consideration of
multiple binding modes is acknowledged as important for com-
putational studies10, but invariably leads to more complex
formalisms11,12. Perhaps for these reasons, little is known about
the molecular mechanisms that control structural stability, to
what extent do ligands preserve flexibility or what are the ener-
getic and functional consequences of rigidity.
It is important to note that structural stability (robustness) is
fundamentally different from thermodynamic stability (i.e.,
binding free energy; ΔGbind). This is eloquently exemplified in the
recent work by Borgia et al., where a protein-protein complex
with picomolar affinity is shown to lack structure2. While ΔGbind
has been the center of attention of scientific research for decades,
little attention has been paid to the factors that determine if a
complex will be tight or loose. The source of structural robustness
must be sought on sharp (and possibly transitory) energetic
barriers that keep the atoms in their positions of equilibrium.
Such hypothetical barriers, like the ones that determine binding
kinetics, could have their origin in intramolecular (i.e., con-
formational rearrangement), bimolecular (e.g., repulsive transi-
tional configurations) or many-body effects (e.g., desolvation)13.
But they will only provide structural stability if the barriers are
steep and located very close to the position of minimum energy.
In that respect, hydrogen bonds (HBs) are ideal candidates
because they have strict distance and angular dependencies14 and
are one of the most frequent interaction types in protein-ligand
complexes15. The contribution of HBs to ΔGbind has been largely
debated in the literature16–20. The current consensus is that it is
highly variable and context dependent, but their contribution to
thermodynamic stability is 1.8 kcal mol−1 at the most17. How-
ever, due to desolvation, the transitional penalty of breaking a HB
can be much larger21. Indeed, we have shown that this is the case
for water-shielded HBs, which can even act as kinetic traps22.
More recently, we have also shown that formation of structurally
robust intermolecular HBs at specific positions is a necessary
condition for binding, and have developed a method to assess the
robustness of individual HBs that is very effective in virtual
screening applications23.
Here, we perform a systematic investigation of the possible role
of HBs as structural anchors of protein-ligand complexes. We
find that most complexes combine a robust anchoring point with
more labile interactions, but cases of completely constricted and
very loose complexes also exist. Our findings not only confirm a
general role of HBs as source of structural stability, but also offer
a new perspective to understand and design ligand-receptor
complexes.
Results
Robust hydrogen bonds are common in protein-ligand com-
plexes. Using Dynamic Undocking (DUck), an MD-based com-
putational procedure23, we have assessed the robustness of every
HB in a set of 79 drug-like protein-ligand complexes from the
Iridium Data Set24. Detailed information about the data set and
the selection criteria is presented in Supplementary Methods and
Supplementary Table 1. Each HB was pulled to a distance of 5 Å,
according to the DUck protocol reported previously23,25. In this
way, we obtain a work value (WQB) that reflects the cost of
breaking each HB. In other words, the WQB value indicates if the
interaction under investigation gives rise to a narrow (local)
minimum in the free-energy landscape, and estimates its depth.
Based on our previous research, we define HBs as robust (i.e.,
capable of providing structural stability) if WQB > 6 kcal mol−1,
labile if WQB < 4 kcal mol−1 and medium otherwise.
The distribution of work values for the entire set of 345 HBs
ranges from 0 to 26 kcal mol−1, with a of maximum probability in
the 0–6 kcal mol−1 region and a gradual decrease thereafter
(Fig. 1a). Noteworthy, more than half HBs (57.4%) are robust. In
order to provide a critical assessment of these results, we have
sought correlation with experimental observables and have also
considered if WQB values might be dominated by the interaction
energies. Larger WQB values imply a narrower minimum and,
thus, restricted mobility, which should translate into a more
localized electron density, that is, lower crystallographic B-factors.
As B-factors are heavily influenced by the refinement methods
used and their absolute values can be meaningless26,27, we have
normalized the B-factor of the ligand atom that makes the
hydrogen bond relative to the average B-factor of the whole
ligand. Encouragingly, atoms forming HBs with larger WQB
values tend to have lower relative B-factors (Supplementary
Fig. 4). A second aspect to consider is whether DUck calculations
merely reflects short-range protein-ligand interaction, or—as
intended—it captures a global effect that considers enthalpic and
entropic contributions from both the solute and the solvent. Lack
of correlation between interaction energies and WQB confirms
that the latter is true (Supplementary Fig. 5). Of particular interest
is to assess the effect of charge reinforcement on HBs, as the
energetic, entropic and solvation terms of neutral hydrogen bonds
and salt bridges are drastically different28. We have classified all
HBs into neutral, mixed (ionic-neutral) and salt bridges (Fig. 2,
Supplementary Data 2). We find that salt bridges are only very
slightly skewed towards more robust interactions than neutral
HBs. The distributions were compared with two sample
Kolmogorov-Smirnov statistical test, yielding p-value of 0.08.
Mixed types are completely indistinguishable from neutral ones
(p-value= 0.42). Unexpectedly, the maximal values are equal
across all three categories. Theoretically, ionic species could
provide even larger energetic barriers because their desolvation
costs are much larger. We speculate that there may be no
biological use for them, as the maximalWQB values observed here
already ensure very robust and long-lived structures.
The distribution of robust HBs is rather inhomogeneous across
complexes, as they have 2.5 on average, but a quarter of the
complexes have none (Fig. 1b). Considering that structural
stability is not a requisite for tight binding and that HBs may not
the only mechanism capable of providing structural stability, it is
striking that 75% of the complexes in this set are anchored
through HBs. A further 14% of complexes present medium values
and only in 9 cases (11%) all their HBs are labile (Supplementary
Fig. 6). Two of those cases are very low affinity complexes. In the
remaining cases, structural stability might be provided by other
mechanisms or may be lacking (see examples in Supplementary
Fig. 6). It is important to note that the level of structural stability
reported here may be overestimated due to the composition of the
data set, entirely derived from X-ray crystallography, a technique
that relies on order to solve structures.
Splitting this analysis by the type of binding site (Fig. 1c–j,
Supplementary Table 2) provides strong indication that the
behavior is dictated by the nature of the receptor. The proportion
of robust complexes increases to 82% in the case of enzyme active
sites, which speaks about the need of keeping the substrate in
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place for efficient catalysis. Nuclear receptors form fewer HBs
with their ligands, but most of them (78%) are robust and all
ligands (100%) are well anchored. In this case, forming a rigid
structure may be necessary to stabilize the AF2 co-regulatory
protein binding surface in an optimal conformation for co-
activator binding29. Carbohydrate binding sites, on the other
hand, form many more HBs with their ligands, but a lower
proportion of robust ones (46%). Finally, in the case of allosteric
ligands, only 40% of complexes are robust, suggesting that these
sites tend to yield looser complexes. As demonstrated in the case
of HIV reverse transcriptase inhibitors (Fig. 3c), lack of robust
HBs does not preclude tight binding. In fact, a multiplicity of
binding modes might be beneficial to preserve binding affinity
when the target is mutated, thus averting resistance30,31. While
the distribution of HB strength between the four types of binding
sites that we have defined is quite different (see Supplementary
Tables 4 and 5 for statistical tests), individual cases can deviate
from the norm (e.g., the allosteric ligand 1YV3 is extremely
robust) and more examples will be needed to reach firm
conclusion about site-dependence.
Strong hydrogen bonds form fragment-sized structural
anchors. To understand whether robust HBs originated from a
single or multiple areas on a ligand, all HBs in each complex were
clustered, based on their distance in space, into fragment-sized
group of atoms (Supplementary Fig. 1). In the majority of com-
plexes (62%) robust HBs were located in a single group, forming a
strong structural anchor (Fig. 4, Supplementary Table 6). The
concentration of robust interactions on a single site, allowing a
some degree of movement to the other parts, minimizes the
entropic costs and can be desirable from a binding affinity per-
spective6. Only 23% of ligands form two structural anchors on
separate regions, though this is more common in the case of
carbohydrate-binding proteins (Supplementary Table 7). Three
exceptional ligands manage to form 3 distinct stable anchors.
Interestingly, they have completely unrelated functions, chemical
structures and physical properties but—at least in two of those
cases—there is a possible functional explanation for the extreme
robustness (Fig. 5).
The distribution of WQB per number of HBs in a local group
(Fig. 4f) is suggestive of cooperative behavior. HBs in isolation
usually do not form robust interactions (mean and median values:
(4.7 ± 4.1) and 3.7 kcal mol−1, respectively), although in excep-
tional cases they can reach values above 10 kcal mol−1. By
contrast, when three or more HBs cluster together, formation of
robust complexes is the most common outcome (mean and
median values: (9.4 ± 5.8) and 9.0 kcal mol−1, respectively). The
HBs within these clusters present relatively similar WQB values
(Supplementary Fig. 7), suggesting that they often behave in a
concerted-like manner. This synergic and mutually dependent
behavior not only ensures higher barriers to dissociation, but is
also well-suited to provide selectivity, as small changes in the
composition or geometry of one of the partners may result in
large changes in magnitude of WQB (see example in Supplemen-
tary Fig. 8).
Protein-fragment complexes are more static than protein-
ligand complexes. The observation that most drug-like ligands
combine tightly bound regions with looser ones makes us wonder
about fragment-sized ligands. Do they balance order and disorder
in some other way (e.g., using fewer attachment points)? Or,
perhaps, depending on the site they bind to, they are either
dynamic or fully constrained? In order to answer these questions,
we have extended our analysis with a set of 27 fragment-protein
complexes (126 individual HBs) from the SERAPhiC dataset32.
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Fig. 1 Frequency of robust HBs in protein-ligand complexes. Histograms of
frequency of HBs by WQB value for: a all simulated HBs (345), c HBs in
enzyme active sites (253), e HBs in the ligand binding site of nuclear
receptors (27), g HBs in carbohydrate binding sites (95), i HBs in allosteric
sites (25). Pie charts showing share of complexes with at least one robust
HB (WQB > 6 kcal mol−1, pink), all labile HBs (WQB < 4 kcal mol−1, green)
or intermediate situations (red) for: b all simulated complexes (79),
d enzymes (56), f nuclear receptors (7), h carbohydrate binding site (14),
j allosteric sites (8)
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Strikingly, we find that fragments have an almost identical
behavior to standard ligands, with 49% of robust HBs (2.3 per
ligand) and 73% of ligands presenting at least one robust inter-
action. The distribution and maximal WQB values are also very
similar (Fig. 6). This indicates that, proportionally, fragments are
more static than standard ligands. This agrees with the observa-
tions that fragments have a more enthalpic binding33 and that
they have a higher proportion of buried HBs34. It also justifies
that, in spite of their low binding affinity, most fragments already
have a well-defined binding mode that serves as a foundation
from which to spread and catch additional interactions. However,
not all fragments form robust interactions and we propose that
these are less suitable as starting points because their binding
mode can change, confounding structure-activity interpretation
and rendering optimization more difficult. Indeed, fragments are
known to change their binding mode when evolved into larger
molecules7,35–39. These may be attempts at building on what is
assumed to be a solid foundation but turns out to be unstable
ground, a possibility that we shall investigate in the future. It
should also be noted that the fraction of well-anchored fragments
may be different for fragments hits that fail to crystallize. The
overlap between X-ray crystallography and other biophysical
screening methods can be rather low40 and progressing fragments
that fail to crystallize is deemed difficult but worthwhile41.
Structural stability is a consequence of binding free energy and
desolvation. Finally, we want to consider what is the origin of the
free energy barrier that causes structural stability. Knowing that a
HB has a large WQB value can be likened to knowing the koff of a
compound without knowing the kon nor ΔGbind: larger values may
indicate that it has a higher transition state (if ΔGbind remains the
same; Fig. 7a), that the complex is thermodynamically more
stable (if kon remains the same; Fig.7b), or a combination thereof.
In this data set, we find that anchoring sites often correspond to
binding hot spots. This is indeed the case for all kinases and
proteases, which have a well-known binding hot spot (Supple-
mentary Table 2, Supplementary Fig. 1), as well as for most
fragments. In such cases, ΔGbind must be a component of WQB,
but there is no correlation between both magnitudes (Supple-
mentary Fig. 9), as already noted23. Thus, we conclude that WQB
must be largely dominated by a transitory dissociation penalty.
The origin of this penalty can be explained by a physical
decoupling between HB rupture and resolvation, as described for
water-shielded hydrogen bonds22. In support of this view, several
studies of the reverse event have identified desolvation of the
binding pocket as the rate-limiting step in ligand
association21,42,43. Indeed, solvent exposed HBs invariably lead to
low WQB values (but note that they can be thermodynamically
stable)44, whereas water-shielding is a necessary but not sufficient
condition of robust HBs (Supplementary Fig. 10).
Discussion
Taken together, our results show that structural stability is a
common property of protein-ligand complexes, but not an
universal one. Cases of loose complexes, while relatively rare
(10-20%), can be found even in a dataset originating exclusively
from X-ray crystallography, a technique that requires structural
homogeneity of the sample. The proportion could be larger
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Fig. 2 Distribution of robustness of HBs by bond’s charge. Histograms presenting distribution ofWQB values in the set of HBs from Iridium DS, divided into
salt bridges, neutral and mixed (ion-neutral) interactions
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Fig. 3 Structures of protein-ligand complexes that form potentially labile structures. Weak hydrogen bonds (WQB < 4 kcal mol−1) marked in green.
a Complex of FXa with inhibitor RPR208707 (PDB id 1F0S; Ki= 18 nM) forms two direct, but labile, HBs with the protein. An additional water-mediated HB
with the catalytic residues (yellow dotted lines) might provide structural stability. b An antibody that recognizes phosphocholine (PDB id 2MCP) forms two
charge-reinforced but labile HBs. A cation-pi interaction (yellow dotted lines) might provide structural stability. c Reverse transcriptase inhibitor (PDB id
1JLA; IC50= 6 nM) forms a single but labile HB with the protein. No other source of structural stability is apparent
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Fig. 4 Distribution of complexes based on the number of structural anchors. Representative of each group is presented in the following image: a 0 anchors:
Chitinase B with inhibitor (PDB id 1W1P; IC50= 5mM); b 1 anchor: Queuine tRNA-ribosyltransferase with inhibitor (PDB id 1N2V; Ki= 83 µM), c 2 anchors:
Vitamin D3 receptor with calcipotriol (PDB id 1S19; Kd= 0.31 nM) and d 3 anchors: Uridylate kinase-AMP (PDB id 1UKZ). Weak hydrogen bonds (WQB
< 4 kcal mol−1) marked in green, medium (4≤WQB < 6 kcal mol−1) in yellow and strong (WQB≥ 6 kcal mol−1) in red. e Pie chart presenting distribution of
number of anchors across the data set. f Distribution of strength of HBs (WQB) versus the number of HBs per group of atoms. The box shows the quartiles
and the whiskers show the rest of distribution excluding outliers. The swarmplot showing all data points is placed in top of the boxplot
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Fig. 5 Structures of completely constricted complexes hint at potential functional role. Cases in the dataset where the ligand presents three structural
anchors are: a Uridilate kinase with AMP (PDB id 1UKZ) where the base, ribose and phosphate of the nucleotide are forming three distinctive centers of
interactions. Structural stability may be necessary for efficient catalysis. b Glucocorticoid receptor ligand-binding domain bound to dexamethasone (PDB id
1M2Z; Kd= 19 nM). The ligand has three regions that form robust interaction, well separated in space but located on the steroid core, thus behaving as a
single rigid block. Structural stability may be necessary for agonistic response. c Influenza virus neuraminidase with inhibitor BCX-1812 (PDB id 1L7F; Ki
single digit nM for various virus strains). Three different functional groups branching out of the pentane scaffold form robust interactions in this extremely
polar and solvent exposed binding site. Weak hydrogen bonds (WQB < 4 kcal mol−1) marked in green, medium (4≤WQB < 6 kcal mol−1) in yellow and
strong (WQB≥ 6 kcal mol−1) in red. Structural anchors are marked with shaded areas: green, red, and blue
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amongst ligands that fail to crystallize. The level of residual
mobility is also larger and more common than the static X-ray
structures lead to think, as also concluded by a recent inde-
pendent study4. In fact, most complexes balance order and
disorder by combining a firm anchor with more relaxed per-
ipheral interactions. Depending on the nature of the ligand and
the binding site, each complex adopts a particular degree of
robustness, that ranges from the very tight (e.g., nuclear
receptor agonists) to the very loose (e.g., HIV-RT allosteric
inhibitors). Each one of these solutions entails important con-
sequences that have, so far, been neglected in drug design. First
of all, a firm anchor provides a framework from which to grow
and capture additional interactions, and the preservation of a
common binding mode helps interpreting structure-activity
relationships. This is particularly important for fragments as
starting points for lead discovery. Secondly, structural robust-
ness can have functional implications, particularly in the case of
receptors, where flexibility has been linked to the agonist/
antagonist response29,45. Thirdly, structural stability implies an
entropic penalty and must be balanced to avoid loss of
potency6,46. Finally, the deep and narrow energetic minima that
cause rigidity also imply large penalties for small recognition
defects, thus increasing the fidelity of the recognition event.
This has been shown for protease-substrate pairs47 and HIV-
protease inhibitors48. In conclusion, this work opens up the
possibility of understanding and designing structural robust-
ness in ligand-receptor complexes. We suggest that robustness
analysis, which can help understand and control the level of
16
a b
All hydrogen bonds (124)
31.5%
19.4%
49.2%
12%
15%
73%
14
12
10
8
6
4
2
0
0 5 10 15 20 25
WQB [kcal/mole]
Max WQB in a complex (26)
>6
4–6
0–4
WQB:
Fr
e
qu
en
cy
Fig. 6 Frequency of robust HBs in protein-fragment complexes. a Histogram
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Fig. 7 Ways of achieving structural robustness. a Idealized representation of two dissociation pathways for complexes with the same ΔGbind and different
desolvation costs. The images above the blue curve shows the state of the system in bound, transition and unbound state of complex with well shielded,
stable hydrogen bond. The images below the green curve show analogous images for the complex with solvent exposed hydrogen bond. b Likewise for
three complexes with the same desolvation cost but different ΔGbind. The images represent complexes with excellent shape complementarity that form
(above the blue curve) or don’t form (below the red curve) favorable hydrogen-bonding pairs. The black dashed line marks the energy cutoff that classifies
bond as structurally stable. c Example of a complex with high dissociation cost due to extreme water-shielding. d Example of a complex with high
dissociation cost due to a tight network of multiple HBs. Weak hydrogen bonds (WQB < 4 kcal mol−1) marked in green and strong (WQB≥ 6 kcal mol−1)
in red
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mobility, should be an essential part of ligand design, not least
because rigid parts demand more precise complementarity than
flexible ones. Qualitatively, a visual inspection can reveal water-
shielded HBs (Fig. 7c) and HB clusters (Fig. 7d), which are tell-
tale signs of robustness. Quantitatively, DUck simulations offer
an inexpensive and automated protocol to calculate WQB.
While HBs appear to be the most common means of achieving
structural robustness, other interaction types (e.g., cation-pi,
water-mediated HBs, halogen bonds) should be considered in
the future.
Methods
Datasets information. See Supplementary Methods and Supplementary
Tables 1–3.
Systems preparation and dynamic undocking. See Supplementary Methods,
Supplementary Figs 1–3 and Supplementary Data 1 and 2.
Results analysis. See Supplementary Figs 4–10 and Supplementary Tables 4–7.
Data availability
All data generated during the current study are available as a part of the Supplementary
Information in the form of sdf and mol2 files.
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